| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Y Nagata, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, ... Cancer cell 6 (2), 117-127, 2004 | 2256 | 2004 |
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer R Nahta, D Yu, MC Hung, GN Hortobagyi, FJ Esteva Nature clinical practice Oncology 3 (5), 269-280, 2006 | 1195 | 2006 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 980 | 2018 |
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells R Nahta, LXH Yuan, B Zhang, R Kobayashi, FJ Esteva Cancer research 65 (23), 11118-11128, 2005 | 964 | 2005 |
| National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers CM Sturgeon, MJ Duffy, UH Stenman, H Lilja, N Brunner, DW Chan, ... Clinical chemistry 54 (12), e11-e79, 2008 | 841* | 2008 |
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells R Nahta, MC Hung, FJ Esteva Cancer research 64 (7), 2343-2346, 2004 | 799 | 2004 |
| Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ... Journal of Clinical Oncology 19 (10), 2587-2595, 2001 | 750 | 2001 |
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ... Journal of Clinical Oncology 20 (7), 1800-1808, 2002 | 749 | 2002 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 679 | 2020 |
| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 632 | 2013 |
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ... Nature medicine 17 (4), 461-469, 2011 | 615 | 2011 |
| Herceptin: mechanisms of action and resistance R Nahta, FJ Esteva Cancer letters 232 (2), 123-138, 2006 | 610 | 2006 |
| TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ... Journal of clinical oncology 30 (21), 2615-2623, 2012 | 605 | 2012 |
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor … AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ... Clinical Cancer Research 13 (1), 228-233, 2007 | 600 | 2007 |
| HER2 therapy: molecular mechanisms of trastuzumab resistance R Nahta, FJ Esteva Breast Cancer Research 8, 1-8, 2006 | 561 | 2006 |
| Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience V Guarneri, DJ Lenihan, V Valero, JB Durand, K Broglio, KR Hess, ... Journal of Clinical Oncology 24 (25), 4107-4115, 2006 | 463 | 2006 |
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ... Journal of clinical oncology 32 (19), 2078-2099, 2014 | 454 | 2014 |
| Residual risk of breast cancer recurrence 5 years after adjuvant therapy AM Brewster, GN Hortobagyi, KR Broglio, SW Kau, CA Santa-Maria, ... Journal of the National Cancer Institute 100 (16), 1179-1183, 2008 | 453 | 2008 |
| Trastuzumab: triumphs and tribulations RE Nahta, FJ Esteva Oncogene 26 (25), 3637-3643, 2007 | 431 | 2007 |
| Immunotherapy and targeted therapy combinations in metastatic breast cancer FJ Esteva, VM Hubbard-Lucey, J Tang, L Pusztai The lancet oncology 20 (3), e175-e186, 2019 | 423 | 2019 |
Lajos PusztaiYale School of Medicine在 yale.edu 的电子邮件经过验证
